Today announced completion of a $13 million Series C financing.

CeNeRx BioPharma raises $13 million through Series C financing to aid TriRima Phase II trial CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative remedies for diseases of the central anxious system , today announced completion of a $13 million Series C financing. ‘These funds will support the Phase II trial of TriRima as monotherapy for treatment-resistant depression,’ said Barry Brand, Chief Executive Officer of CeNeRx.’ Related StoriesEstradiol fluctuation may enhance emotional sensitivity to psychosocial stress during menopausal transitionUCLA launches second Grand Challenge to reduce health insurance and economic impacts of depressionComputerised cognitive behavioural therapy apt to be ineffective in despair treatmentCeNeRx is getting ready to conduct a Phase II trial with a better formulation of its business lead product applicant TriRima for treatment-resistant depressive disorder..Dalton’s function comprised two research. In the first, experts placed autistic children in a MRI scanner and demonstrated them images of faces with both psychological and neutral expressions. The kids had to press 1 of 2 buttons to point whether a encounter demonstrated a blank or expressive encounter. Through the entire process, the experts used precise eye-monitoring technology to measure specifically which parts of the facial skin study participants were considering and for just how long.